WO2019178057A1 - Procédés de traitement du cancer à l'aide de burkholderia - Google Patents

Procédés de traitement du cancer à l'aide de burkholderia Download PDF

Info

Publication number
WO2019178057A1
WO2019178057A1 PCT/US2019/021795 US2019021795W WO2019178057A1 WO 2019178057 A1 WO2019178057 A1 WO 2019178057A1 US 2019021795 W US2019021795 W US 2019021795W WO 2019178057 A1 WO2019178057 A1 WO 2019178057A1
Authority
WO
WIPO (PCT)
Prior art keywords
carcinoma
cancer
cell
mage
leukemia
Prior art date
Application number
PCT/US2019/021795
Other languages
English (en)
Inventor
Brian Goodman
Christopher J.H DAVITT
Original Assignee
Evelo Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences, Inc. filed Critical Evelo Biosciences, Inc.
Priority to US16/980,339 priority Critical patent/US20210113628A1/en
Publication of WO2019178057A1 publication Critical patent/WO2019178057A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Abstract

L'invention concerne des procédés et des compositions associés à des bactéries du genre Burkholderia utiles en tant qu'agents thérapeutiques.
PCT/US2019/021795 2018-03-12 2019-03-12 Procédés de traitement du cancer à l'aide de burkholderia WO2019178057A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/980,339 US20210113628A1 (en) 2018-03-12 2019-03-12 Intracellular delivery of biomolecules to modify immune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862641691P 2018-03-12 2018-03-12
US62/641,691 2018-03-12

Publications (1)

Publication Number Publication Date
WO2019178057A1 true WO2019178057A1 (fr) 2019-09-19

Family

ID=65904607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/021795 WO2019178057A1 (fr) 2018-03-12 2019-03-12 Procédés de traitement du cancer à l'aide de burkholderia

Country Status (2)

Country Link
US (1) US20210113628A1 (fr)
WO (1) WO2019178057A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000315A2 (pt) * 2018-07-11 2021-08-03 Actym Therapeutics, Inc. cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
AU2020228648A1 (en) 2019-02-28 2021-10-14 Sqz Biotechnologies Company Delivery of biomolecules to PBMCs to modify an immune response
US11679388B2 (en) 2019-04-08 2023-06-20 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
WO2007044406A2 (fr) * 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methodes permettant de stimuler une reponse immunitaire au moyen d'un systeme de distribution d'antigenes bacteriens
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011073956A2 (fr) * 2009-12-17 2011-06-23 Gene Bridges Gmbh Hôtes hétérologues
US8268798B2 (en) 2007-11-15 2012-09-18 Alcon Research, Ltd. Low density lipoprotein receptor-mediated siRNA delivery
US8283461B2 (en) 2004-03-05 2012-10-09 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
US8313772B2 (en) 2010-02-24 2012-11-20 Arrowhead Madison Inc. Compositions for targeted delivery of siRNA
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US8426554B2 (en) 2010-12-29 2013-04-23 Arrowhead Madison Inc. In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2013148258A1 (fr) * 2012-03-29 2013-10-03 Jerome Schentag Formulations de vaccination orale spécifiques à un site gastro-intestinal actives sur l'iléon et l'appendice
US20160022592A1 (en) 2013-03-14 2016-01-28 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US8283461B2 (en) 2004-03-05 2012-10-09 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
WO2007044406A2 (fr) * 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methodes permettant de stimuler une reponse immunitaire au moyen d'un systeme de distribution d'antigenes bacteriens
US8268798B2 (en) 2007-11-15 2012-09-18 Alcon Research, Ltd. Low density lipoprotein receptor-mediated siRNA delivery
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011073956A2 (fr) * 2009-12-17 2011-06-23 Gene Bridges Gmbh Hôtes hétérologues
US8313772B2 (en) 2010-02-24 2012-11-20 Arrowhead Madison Inc. Compositions for targeted delivery of siRNA
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US8426554B2 (en) 2010-12-29 2013-04-23 Arrowhead Madison Inc. In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
WO2013148258A1 (fr) * 2012-03-29 2013-10-03 Jerome Schentag Formulations de vaccination orale spécifiques à un site gastro-intestinal actives sur l'iléon et l'appendice
US20160022592A1 (en) 2013-03-14 2016-01-28 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"Guide to Huge Computers", 1994, ACADEMIC PRESS
ACHTMAN M; WAGNER M: "Microbial diversity and the genetic nature of microbial species", NAT. REV. MICROBIOL., vol. 6, 2008, pages 431 - 440
ATSCHUL, S. F. ET AL., J MOLEC BIOL, vol. 215, 1990, pages 403
BERNSTEIN E ET AL.: "The rest is silence", RNA, vol. 7, 2002, pages 1509 - 1521, XP009010244
BHOOPALAM ET AL.: "Effect of dextran-S (alpha, 1-3 dextran) on the growth of plasmacytomas MOPC-104E and J558", J. IMMUNOL., vol. 125, no. 4, 1980, pages 1454 - 8
BRUMMELKAMP: "A system for stable expression of short interfering RNAs in mammalian cells", SCIENCE, vol. 296, 2002, pages 550 - 553, XP002626048, DOI: doi:10.1126/science.1068999
CAERS ET AL.: "Of mice and men: disease models of multiple myeloma", DRUG DISCOVERY TODAY: DISEASE MODELS, vol. 1, no. 4, 2004, pages 373 - 380, XP004698912, DOI: doi:10.1016/j.ddmod.2004.11.010
CARILLO ET AL., SIAM J APPLIED MATH, vol. 48, 1988, pages 1073
CHAI ET AL.: "Bioluminescent orthotopic model of pancreatic cancer progression", J. VIS. EXP., vol. 76, 2013, pages 50395
CLAESSON MJ; WANG Q; O'SULLIVAN O; GREENE-DINIZ R; COLE JR; ROSS RP; O'TOOLE PW: "Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions", NUCLEIC ACIDS RES, vol. 38, 2010, pages e200, XP055250083, DOI: doi:10.1093/nar/gkq873
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. I, 1984, pages 387
EUSTÁQUIO ALESSANDRA S ET AL: "Biosynthetic engineering and fermentation media development leads to gram-scale production of spliceostatin natural products inBurkholderiasp", METABOLIC ENGINEERING, vol. 33, 2016, pages 67 - 75, XP029375526, ISSN: 1096-7176, DOI: 10.1016/J.YMBEN.2015.11.003 *
GONZALEZ-CARMONA ET AL.: "CD40 ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo", HEPATOLOGY, vol. 48, no. 1, 2008, pages 157 - 168
GUO ET AL.: "Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles", ASC NANO, vol. 8, no. 6, 2014, pages 5670 - 5681
HANAI ET AL., ANN NY ACAD SCI., vol. 1082, 2006, pages 9 - 17
HANNON, GJ: "RNA Interference", NATURE, vol. 418, 2002, pages 244 - 251, XP002979088, DOI: doi:10.1038/418244a
HOUOT ET AL.: "T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy", BLOOD, vol. 113, no. 15, 2009, pages 3546 - 3552, XP055097946, DOI: doi:10.1182/blood-2008-07-170274
HUTVAGNER G ET AL.: "RNAi: Nature abhors a double-strand", CURR. OPIN. GENETICS & DEVELOPMENT, vol. 12, pages 225 - 232, XP002329959, DOI: doi:10.1016/S0959-437X(02)00290-3
JY LEE ET AL., SCI REP., vol. 6, 6 May 2016 (2016-05-06), pages 25543
KAWATA ET AL., MOL CANCER THER., vol. 7, no. 9, 2008, pages 2904 - 12
KONSTANTINIDIS KT; RAMETTE A; TIEDJE JM: "The bacterial species definition in the genomic era", PHILOS TRANS R SOC LOND B BIOL SCI, vol. 361, 2006, pages 1929 - 1940
LATTANZIO ET AL.: "Defective Development of Pristane-Oil Induced Plasmacytomas in Interleukin-6-Deficient BALB/C Mice", AM. J. PATHOLOGY, vol. 151, no. 3, 1997, pages 689696
LEE NS; DOHJIMA T; BAUER G; LI H; LI M-J; EHSANI A; SALVATERRA P; ROSSI J: "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells", NATURE BIOTECHNOL., vol. 20, 2002, pages 500 - 505
LEEKHA ET AL.: "General Principles of Antimicrobial Therapy", MAYO CLIN PROC., vol. 86, no. 2, 2011, pages 156 - 167, XP055372896, DOI: doi:10.4065/mcp.2010.0639
MALETZKI ET AL.: "Pancreatic cancer regression by intratumoral injection of live streptococcus pyogenes in a syngeneic mouse model", GUT, vol. 57, 2008, pages 483 - 491
MINAKUCHI ET AL., NUCLEIC ACIDS RES., vol. 32, no. 13, 2004, pages el09
MIYAGISHI M; TAIRA K: "U6-promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells", NATURE BIOTECHNOL., vol. 20, 2002, pages 497 - 500, XP002961100, DOI: doi:10.1038/nbt0502-497
PADDISON PJ; CAUDY AA; BERNSTEIN E; HANNON GJ; CONKLIN DS: "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells", GENES & DEV., vol. 16, 2002, pages 948 - 958
PARTECKE ET AL.: "A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/B16 mouse using the Panc02 and 6606PDA cell lines", EUR. SURG. RES., vol. 47, no. 2, 2011, pages 98 - 107
PAUL CP; GOOD PD; WINER I; ENGELKE DR: "Effective expression of small interfering RNA in human cells", NATURE BIOTECHNOL., vol. 20, 2002, pages 505 - 508, XP001121066, DOI: doi:10.1038/nbt0502-505
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444
POTTER ET AL.: "Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens", J. NATL. CANCER INST., vol. 71, no. 2, 1983, pages 391 - 5
PROPST KL ET AL., INFECT IMMUN., vol. 78, no. 7, July 2010 (2010-07-01), pages 3136 - 43
R.M. ATLAS: "Handbook of Microbiological Media", 2010, CRC PRESS
SAARELA ET AL., J. APPLIED MICROBIOLOGY, vol. 99, 2005, pages 1330 - 1339
SILINDIR M. ET AL., FABAD J. PHARM. SCI., vol. 34, 2009, pages 43 - 53
SUI G; SOOHOO C; AFFAR E-B; GAY F; SHI Y; FORRESTER WC; SHI Y: "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 6, 2002, pages 5515 - 5520, XP002964701, DOI: doi:10.1073/pnas.082117599
TAO ET AL., IMAGABLE 4T1 MODEL FOR THE STUDY OF LATE STAGE BREAST CANCER, vol. 8, 2008, pages 288
WANG ET AL.: "IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma", ONCOLMMUNOLOGY, vol. 4, no. 7, 2015, pages el014232 - 1,9
WANG ET AL.: "Systemic dissemination of viral vectors during intratumoral injection", MOLECULAR CANCER THERAPEUTICS, vol. 2, no. 11, 2003, XP003005068
YU J-Y; DERUITER SL; TURNER DL: "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 9, 2002, pages 6047 - 6052, XP002332096, DOI: doi:10.1073/pnas.092143499

Also Published As

Publication number Publication date
US20210113628A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
US10576111B2 (en) Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097
US20190314427A1 (en) Methods of treating cancer using parabacteroides
US20210330718A1 (en) Composition and methods for treating cancer and immune disorders using veillonella bacteria
WO2018112365A2 (fr) Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
WO2019099482A1 (fr) Compositions et méthodes de traitement d'une maladie à l'aide d'une souche de blautia
US20190365830A1 (en) Methods of treating cancer
US20200121739A1 (en) Bacteria for treating cancer
WO2019152667A1 (fr) Compositions et méthodes de traitement de troubles immunitaires à l'aide de bactéries lachnospiraceae
US11241461B2 (en) Treating cancer using a blautia strain
WO2019169181A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de lactobacillus salivarius
WO2019178487A2 (fr) Compositions et méthodes de traitement d'une maladie à l'aide de klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178490A1 (fr) Compositions et procédés pour traiter le cancer et l'inflammation utilisant klebsiella oxytoca
WO2021022110A1 (fr) Induction d'effets immunitaires à l'aide de bactéries du genre bifidobacterium
WO2019178055A1 (fr) Vésicules extracellulaires provenant de burkholderia
WO2019178494A1 (fr) Compositions et méthodes de traitement du cancer et de l'inflammation à l'aide de tyzzerella nexilis
WO2019178057A1 (fr) Procédés de traitement du cancer à l'aide de burkholderia
WO2019169138A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de paraclostridium benzoelyticum
WO2019169160A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de ruminococcus gnavus
WO2019169143A1 (fr) Compositions et méthodes de traitement du cancer à l'aide de t uricibacter sanguinis
WO2019169168A1 (fr) Compositions et méthodes de traitement du cancer à l'aide d'agathobaculum
WO2019075452A1 (fr) Identification de bactéries pour la cancérothérapie
WO2020006216A1 (fr) Compositions et méthodes de traitement du cancer faisant appel à des bactéries neisseria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19713320

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19713320

Country of ref document: EP

Kind code of ref document: A1